Business
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced
About this update from Ataibeckley Inc.
[{"type":"text","content":"NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in mental health and support promising graduate students and other trainees in furthering their professional careers in this emerging field. Over the five-year program, fellows will have access to MGH’s innovative resources and expertise in neuroimaging technologies, cognitive neuroscience, cellular and molecular neurobiology, and clinical trial design, enabling them to pursue the discovery, optimization, and translation of novel experimental psychedelic neurotherapeutics. The first cohort is comprised of five graduate students whose research projects will focus primarily on mechanistic studies of psychedelics and associated therapeutic interventions, including: chemical biology approaches to investigate endogenous psychedelic compounds, such as N,N-dimethyltryptamine (DMT), as well as enzymatic machinery required for biosynthesis in an array of both human and rodent cell typesthe ethnopharmacology of a Central and South American psychedelic planta systems neuroscience approach to the modeling of the brain after the administration of a psychedelic compoundusing epidemiological and observational data to explore the potential of psychedelic treatments for addressing suicidal tendencies and behaviorsthe effects of psilocybin assisted psychotherapy on irritable bowel syndrome (IBS) “Being awarded this fellowship has given me the flexibility to do unprecedented research with a cutting-edge intervention that has yet to be well-understood,” said graduate student, Clare Shaffer, upon being awarded the atai Fellowship. The fellows, primarily sourced from M.D./Ph.D. programs at Greater Boston institutions, were selected through a competitive review process based on their proposed research project and their vision of the impact of psychedelic research on the field of mental health. It was also important to MGH and atai that Fellows be selected with a focus...